About Dr. Liang Xiaohua
Dr. Liang Xiaohua (梁晓华) is the Director of the Department of Medical Oncology at Huashan Hospital, Fudan University — one of Shanghai's leading academic cancer centers. A nationally recognized authority in thoracic oncology and gastrointestinal cancers, Dr. Liang specializes in precision medicine, targeted therapy, and immunotherapy for solid tumors, with a particular focus on lung cancer, colorectal cancer, and gastric cancer.
Under his leadership, Huashan's medical oncology department has built a reputation for individualized, evidence-based cancer care that integrates the latest advances in molecular profiling, biomarker-driven treatment selection, and clinical trial access. Dr. Liang is known for his ability to navigate complex, multi-line treatment scenarios and to identify therapeutic options for patients who have exhausted standard regimens — making him a sought-after resource for second opinions and salvage therapy planning.
Hospital Affiliation
Huashan Hospital, Fudan University is consistently ranked among China's top hospitals. Its oncology program benefits from close integration with the hospital's neurosurgery, neurology, and infectious disease departments — enabling comprehensive management of cancer patients with neurological complications, brain metastases, and infection-related comorbidities. The department has access to next-generation sequencing (NGS) for tumor molecular profiling, PD-L1 and other biomarker testing, and a portfolio of ongoing clinical trials across multiple tumor types.
Clinical Expertise
- Lung cancer — NSCLC and SCLC; EGFR, ALK, ROS1, KRAS, MET targeted therapy; PD-1/PD-L1 immunotherapy; brain metastasis management
- Colorectal cancer — RAS/BRAF/MSI profiling; FOLFOX, FOLFIRI, bevacizumab, cetuximab; liver metastasis coordination
- Gastric & gastroesophageal junction cancer — HER2-targeted therapy, ramucirumab, nivolumab; perioperative chemotherapy
- Pancreatic cancer — FOLFIRINOX, gemcitabine/nab-paclitaxel; BRCA-targeted therapy; palliative care coordination
- Hepatocellular carcinoma — sorafenib, lenvatinib, atezolizumab/bevacizumab; TACE coordination
- Head & neck cancers — platinum-based regimens, cetuximab, pembrolizumab; multidisciplinary coordination with ENT and radiation oncology
- Breast cancer — hormone receptor-positive, HER2-positive, and triple-negative subtypes; CDK4/6 inhibitors, T-DM1, PARP inhibitors
- Unknown primary cancer — molecular profiling-guided treatment; tissue of origin testing
- Immunotherapy toxicity management — immune-related adverse events (irAEs); steroid protocols; multidisciplinary toxicity management
- Clinical trial access — enrollment in phase I–III trials for novel targeted agents and immunotherapy combinations
Academic & Research Contributions
Dr. Liang Xiaohua has authored numerous peer-reviewed publications in leading oncology journals including the Journal of Clinical Oncology, Annals of Oncology, and Cancer. His research focuses on biomarker-driven treatment selection in lung and gastrointestinal cancers, the optimization of immunotherapy regimens, and the management of treatment-related toxicities in Chinese cancer populations.
He is an active member of the Chinese Society of Clinical Oncology (CSCO) and has contributed to the development of national clinical guidelines for lung cancer and colorectal cancer. Dr. Liang is a regular presenter at major oncology conferences including ASCO, ESMO, and CSCO, and has served as a principal investigator on multiple multicenter clinical trials evaluating novel targeted agents and immunotherapy combinations in Chinese patients.
His work on the real-world efficacy of EGFR-targeted therapy in Chinese lung cancer patients — a population with significantly higher EGFR mutation rates than Western cohorts — has been particularly influential, providing data that informs treatment decisions for Asian patients globally.
Why International Patients Choose Dr. Liang
International patients seek Dr. Liang's expertise for second opinions on complex cancer diagnoses, access to clinical trials not available in their home countries, and treatment planning for cancers that have progressed on standard regimens. China's significantly higher prevalence of EGFR-mutant lung cancer means that Huashan's oncology team has unparalleled experience with targeted therapy management — experience that directly benefits international patients with these mutations.
The cost advantage is also substantial: comprehensive molecular profiling, targeted therapy, and immunotherapy at Huashan Hospital are available at a fraction of the cost of equivalent treatment in the United States or Europe, without compromising on drug quality, clinical expertise, or monitoring standards. For patients facing high out-of-pocket costs at home, this can make a meaningful difference in their ability to access optimal care.
CMCS coordinates all aspects of the oncology visit, from medical record translation and appointment scheduling to treatment coordination and remote follow-up support after patients return home.
What to Expect at Your Consultation
Consultations with Dr. Liang begin with a comprehensive review of pathology reports, molecular profiling results, imaging, and prior treatment history. CMCS will arrange certified translation of all records in advance. Where additional molecular testing or imaging is needed, this can typically be arranged within 24–48 hours. Dr. Liang will provide a detailed treatment plan including drug options, clinical trial eligibility, and monitoring protocols — all summarized in English for sharing with your home oncologist.
Frequently Asked Questions
Can Dr. Liang provide a second opinion on my cancer diagnosis and treatment plan?
Yes. Second-opinion consultations are a core part of Dr. Liang's international patient practice. CMCS will arrange translation of your pathology and imaging reports and coordinate a comprehensive review appointment.
Does Huashan have access to the latest targeted therapies and immunotherapy drugs?
Yes. Huashan Hospital has access to all major approved targeted agents and immunotherapy drugs, as well as investigational agents through clinical trials. Many drugs approved in China are available at significantly lower cost than in Western markets.
Can I enroll in a clinical trial at Huashan?
Eligibility for clinical trials depends on your specific diagnosis, prior treatment history, and current health status. CMCS will work with Dr. Liang's team to assess your eligibility during the consultation process.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides end-to-end support for international patients seeking oncology care with Dr. Liang Xiaohua at Huashan Hospital, including priority appointment scheduling, certified medical translation, pathology and imaging review coordination, and post-consultation follow-up. Contact us at contract@medicalsh.com, WeChat: gezhanglao, or visit medicalsh.com.
댓글 0개